Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financial activity by Mersana Therapeutics, Hyperion Therapeutics, Atterocor and Exelixis.